HIV, visceral leishmaniasis and Parkinsonism combined with diabetes mellitus and hyperuricaemia: A case report [PDF]
Krishna Pandey +7 more
core +1 more source
Miltefosine Treatment of Cutaneous Leishmaniasis
Jaime A, Soto, Jonathan D, Berman
openaire +2 more sources
Therapeutic challenges in relapsing cutaneous and visceral leishmaniasis caused by Leishmania (Mundinia) martiniquensis in patients with advanced HIV disease from Southern Thailand. [PDF]
Phadungsaksawasdi K +11 more
europepmc +1 more source
Cutaneous leishmaniasis: epidemiology, treatment access and translational challenges of topical therapies. [PDF]
Carrer DC, Papera F, Ríos DN.
europepmc +1 more source
Evaluating LeishPepThera (PepA) as an immuno-therapeutic for <i>Leishmania major</i> infection. [PDF]
Khandibharad S, Singh S.
europepmc +1 more source
Insights on genomic profiles of drug resistance and virulence in a cohort of Leishmania infantum isolates from the Mediterranean area. [PDF]
Carrasco-Martin M +20 more
europepmc +1 more source
Successful Treatment with Miltefosine of Disseminated Cutaneous Leishmaniasis in a Severely Immunocompromised Patient Infected with HIV-1 [PDF]
Baumann, Doris +9 more
core
Light, Dyes, and Action: Photodynamic Inactivation of <i>Leishmania amazonensis</i> Using Methylene Blue, New Methylene Blue, and Novel Ruthenium-Based Derivatives. [PDF]
Vasco-Dos-Santos DR +7 more
europepmc +1 more source
Investigation of the antifungal activity of panobinostat, tamoxifen, and miltefosine alone and in combination with some conventional antifungal drugs against fluconazole-resistant <i>Candida</i> species. [PDF]
Amirzadeh-Ghasemi F +8 more
europepmc +1 more source
Optimization and prioritization of paediatric drugs for visceral leishmaniasis. [PDF]
Masini T +10 more
europepmc +1 more source

